DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$21.34
$0.34(9.80%)
At close: 4:00 PM EST
$21.34
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$7.53 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)260.63K
Market Cap
$1.15B
Enterprise Value$542.88M
Total Cash (Recent Filing)$194.17M
Total Debt (Recent Filing)$21.68M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
May 04, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding55,670,418
10 Day Avg. Volume198,256
30 Day Avg. Volume260,632
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)3.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.42
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.74
Enterprise Value/Ebitda-4.04
Forecast
1Y Price Target
$39.64Price Target Upside85.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$5.34M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityLate-stage clinical trial efficacy that surpassed regulatory success criteria, combined with consistent safety and low discontinuation rates, bolsters the approval case and clinician confidence.
Commercial Readiness And AdoptionAt-home application, low risk of severe allergic reactions, and family-friendly tolerability support potential strong patient and physician adoption, with recent financing enabling pre-commercial inventory and hiring.
Regulatory PathwayUpcoming regulatory filings and a pediatric safety study for the company's Viaskin Peanut may advance approval prospects and expand access for older pediatric patients.
Bears Say
Cash Burn And Financing RiskHigh cash burn and a relatively short cash runway increase the likelihood that additional capital will be required before commercialization, creating dilution risk for shareholders.
Commercial And Label UncertaintyUncertainty remains about how trial results will translate into label differences, real-world adherence, physician positioning versus other active options, and long-term durability, leaving commercial prospects unclear.
Valuation AdjustmentAnalyst identified a modeling error related to carrying forward French corporate tax losses, leading to an updated valuation and a lower price target.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $7.53 and its highest was $26.18 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $1.15B.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is May 04, 2026 which is in 5 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Mar 26, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.062.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.15.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 55,670,418 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -1.039%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.64 (85.73% Upside)
$39.64 (85.73% Upside)
Blogger Sentiment
Neutral
DBVT Sentiment 50%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $2.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.41%
12-Months-Change
Fundamentals
Return on Equity
-189.50%
Trailing 12-Months
Asset Growth
255.96%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$39.64
▲(85.73% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
PureTech Health
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
66.47% Insiders
3.66% Mutual Funds
0.10% Other Institutional Investors
29.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---